Title
Date
- Running Bispecific Antibody and T-Cell Engager Trials in Korea: A Sponsor’s Regulatory and Operational Playbook
- FDA and EMA’s 2026 AI and Bayesian Guidance: What the New Regulatory Convergence Means for Clinical Trial Design in Korea
- Is Your Combination Product Drug-Led or Device-Led in Korea? A Sponsor’s Guide to MFDS Classification and Dual-Track Review
- The First PROTAC Drug is Now FDA-Approved: What Vepdegestrant’s 2026 Breakthrough Means for the Next Wave of Targeted Protein Degradation Trials
- GLP-1 Drugs and Cancer: What ASCO 2026 Data Means for Oncology Clinical Trials in Korea
- What Happens When Korean Pharma Companies Enter Global Clinical Trials Without a CRO
- CRO Outsourcing Costs: What Quotations in Korea Often Leave Out
- Choosing the Right CRO in Korea: A Sponsor’s Evaluation Guide for 2026